Early Drosophila development requires two receptor tyrosine kinase (RTK) pathways: the Torso and the Epidermal growth factor receptor (EGFR) pathways, which regulate terminal and dorsal-ventral patterning, respectively. Previous studies have shown that these pathways, either directly or indirectly, lead to post-transcriptional downregulation of the Capicua repressor in the early embryo and in the ovary. Here, we show that both regulatory effects are direct and depend on a MAPK docking site in Capicua that physically interacts with the MAPK Rolled. Capicua derivatives lacking this docking site cause dominant phenotypes similar to those resulting from loss of Torso and EGFR activities. Such phenotypes arise from inappropriate repression of genes normally expressed in response to Torso and EGFR signaling. Our results are consistent with a model whereby Capicua is the main nuclear effector of the Torso pathway, but only one of different effectors responding to EGFR signaling. Finally, we describe differences in the modes of Capicua downregulation by Torso and EGFR signaling, raising the possibility that such differences contribute to the tissue specificity of both signals.

Background: PPAR␣ is a distinctive marker of the brown-versus-white fat phenotype. Results: PPAR␣ induces PGC-1␣ gene transcription in brown adipocytes through mechanisms involving PRDM16. Conclusion: PPAR␣ regulates brown fat thermogenesis via induction of PGC-1␣ and PRDM16 gene expression. Significance: Activation of PGC-1␣ by PPAR␣ provides a molecular mechanism for concerted induction of thermogenic genes (UCP1, mitochondrial genes, and lipid oxidation genes) in brown fat.

Sirt3 (silent mating type information regulation 2, homolog 3), a member of the sirtuin family of protein deacetylases with multiple actions on metabolism and gene expression is expressed in association with brown adipocyte differentiation. Using Sirt3-null brown adipocytes, we determined that Sirt3 is required for an appropriate responsiveness of cells to noradrenergic, cAMP-mediated activation of the expression of brown adipose tissue thermogenic genes. The transcriptional coactivator Pgc-1␣ (peroxisome proliferator-activated receptor-␥ coactivator-1␣) induced Sirt3 gene expression in white adipocytes and embryonic fibroblasts as part of its overall induction of a brown adipose tissue-specific pattern of gene expression. In cells lacking Sirt3, Pgc-1␣ failed to fully induce the expression of brown fat-specific thermogenic genes. Pgc-1␣ activates Sirt3 gene transcription through coactivation of the orphan nuclear receptor Err (estrogen-related receptor)-␣, which bound the proximal Sirt3 gene promoter region. Err␣ knockdown assays indicated that Err␣ is required for full induction of Sirt3 gene expression in response to Pgc-1␣. The present results indicate that Pgc-1␣ controls Sirt3 gene expression and this action is an essential component of the overall mechanisms by which Pgc-1␣ induces the full acquisition of a brown adipocyte differentiated phenotype.Brown adipose tissue plays a major role in the control of energy expenditure in mammals. The specific mitochondrial uncoupling that is characteristic of brown adipocytes creates a specialized cell type adapted to promoting energy expenditure in response to cold or overfeeding. In contrast, white adipocytes are specialized in the accumulation of metabolic energy in the form of lipids. Brown adipocytes respond to noradrenergic stimulation through ␤-adrenoreceptors in the cell surface, which bind norepinephrine and signal through adenylate cyclase to increase cAMP and activate protein kinase A. Ultimately, this signaling cascade lead to activation of hormonesensitive lipase, induction of the expression of the gene for uncoupling protein-1 (Ucp1) 2 and other genes involved in thermogenesis, and activation of the Ucp1-dependent uncoupling of mitochondria (1). Acquisition of the cellular machinery typical of brown adipocyte thermogenic function is a highly plastic process. In fact, pre-adipocytes or even white adipocytes may acquire brown adipocyte properties in response to developmental or environment regulators. Several molecular agents have been reported to promote brown adipocyte differentiation, central among them is Pgc-1␣.Pgc-1␣ is a transcriptional coactivator that plays a major role in the acquisition of the specific brown adipocyte phenotype. Pgc-1␣ coactivates nuclear receptors and transcription factors and thereby activates genes involved in thermogenesis (e.g. Ucp1), lipid oxidation, and mitochondrial oxidation, which are associated with the specific thermogenic function of brown adipose tissue (2). For instance, when white adipocytes are forced to expres...

Fibroblast growth factor 21 (FGF21) is a member of the FGF family that reduces glycemia and ameliorates insulin resistance. Adipose tissue is a main target of FGF21 action. Obesity is associated with a chronic proinflammatory state. Here, we analyzed the role of proinflammatory signals in the FGF21 pathway in adipocytes, evaluating the effects of TNF-α on β-Klotho and FGF receptor-1 expression and FGF21 action in adipocytes. We also determined the effects of rosiglitazone on β-Klotho and FGF receptor-1 expression in models of proinflammatory signal induction in vitro and in vivo (high-fat diet-induced obesity). Because c-Jun NH(2)-terminal kinase 1 (JNK1) serves as a sensing juncture for inflammatory status, we also evaluated the involvement of JNK1 in the FGF21 pathway. TNF-α repressed β-Klotho expression and impaired FGF21 action in adipocytes. Rosiglitazone prevented the reduction in β-Klotho expression elicited by TNF-α. Moreover, β-Klotho levels were reduced in adipose tissue from high-fat diet-induced obese mice, whereas rosiglitazone restored β-Klotho to near-normal levels. β-Klotho expression was increased in white fat from JNK1(-/-) mice. The absence of JNK1 increased the responsiveness of mouse embryonic fibroblast-derived adipocytes and brown adipocytes to FGF21. In conclusion, we show that proinflammatory signaling impairs β-Klotho expression and FGF21 responsiveness in adipocytes. We also show that JNK1 activity is involved in modulating FGF21 effects in adipocytes. The impairment in the FGF21 response machinery in adipocytes and the reduction in FGF21 action in response to proinflammatory signals may play important roles in metabolic alterations in obesity and other diseases associated with enhanced inflammation.

There is accumulating evidence that omega-3 fatty acids may modulate immune responses. When monocytes were differentiated to dendritic cells (DCs) in the presence of docosahexaenoic acid (DHA), the expression of costimulatory and antigen presentation markers was altered in a concentration-dependent way, positively or negatively, depending on the markers tested and the maturation stage of the DCs. Changes induced by eicosapentaenoic acid and linoleic acid were similar but less intense than those of DHA, whereas oleic acid had almost no effect. DHA-treated, mature DCs showed inhibition of IL-6 expression and IL-10 and IL-12 secretion, and their lymphoproliferative stimulation capacity was impaired. The phenotypic alterations of DCs induced by DHA were similar to those already reported for Rosiglitazone (Rosi), a peroxisome proliferator-activated receptor gamma (PPAR gamma) activator, and the retinoid 9-cis-retinoic acid (9cRA), a retinoid X receptor (RXR) activator. Moreover, DHA induced the expression of PPAR gamma target genes pyruvate dehydrogenase kinase-4 and aP-2 in immature DCs. The combination of DHA with Rosi or 9cRA produced additive effects. Furthermore, when DCs were cultured in the presence of a specific PPAR gamma inhibitor, all of the changes induced by DHA were blocked. Together, these results strongly suggest that the PPAR gamma:RXR heterodimer is the pathway component activated by DHA to induce its immunomodulatory effect on DCs.

Type 2 diabetes results from progressive pancreatic ␤-cell dysfunction caused by chronic insulin resistance. Activation of c-Jun NH 2 -terminal kinase (JNK) inhibits insulin signaling in cultured cells and in vivo and thereby promotes insulin resistance. Conversely, the peroxisome proliferator-activated receptor (PPAR) ␥ synthetic ligands thiazolidinediones (TZDs) enhance insulin sensitivity. Here, we show that the TZDs rosiglitazone and troglitazone inhibit tumor necrosis factor-␣-induced JNK activation in 3T3-L1 adipocytes. Our results indicate that PPAR␥ mediates this inhibitory action because 1) it is reproduced by other chemically unrelated PPAR␥ agonist ligands and blocked by PPAR␥ antagonists; 2) it is enhanced by PPAR␥ overexpression; and 3) it is abrogated by PPAR␥ RNA interference. In addition, we show that rosiglitazone inhibits JNK activation and promotes the survival of pancreatic ␤-cells exposed to interleukin-1␤. In vivo, the abnormally elevated JNK activity is inhibited in peripheral tissues by rosiglitazone in two distinct murine models of obesity. Moreover, rosiglitazone fails to enhance insulin-induced glucose uptake in primary adipocytes from ob/ob JNK1 ؊/؊ mice. Accordingly, we demonstrate that the hypoglycemic action of rosiglitazone is abrogated in the diet-induced obese JNK1-deficient mice. In summary, we describe a novel mechanism based on targeting the JNK signaling pathway, which is involved in the hypoglycemic and potentially in the pancreatic ␤-cell protective actions of TZDs/PPAR␥. Diabetes

In the present study, a comparative assessment of the effects of efavirenz (EFV) and lopinavir/ritonavir (LPV/r; 4:1) on human adipocytes in culture has been performed. Human pre-adipocytes were treated with EFV or LPV/r during or after adipogenic differentiation. Acquisition of adipocyte morphology, expression of gene markers of mitochondrial toxicity, adipogenesis and inflammation, and release of adipokines and cytokines to the medium were measured. Results indicated that EFV and LPV/r impaired adipocyte differentiation in association with a reduction in transcript levels for adipogenic differentiation genes (adiponectin, lipoprotein lipase, leptin) and master regulators of adipogenesis (PPAR, C/EBP). The effects were greater with EFV than LPV/r. Both LPV/r and EFV induced increases in monocytechemoattactant protein-1 (MCP-1) mRNA levels, but the effect was greater with EFV. Similarly, the release of proinflammatory cytokines and other inflammation-related molecules (interleukins 6 and 8, MCP-1, PAI-1) was enhanced to a much higher degree by EFV than by LPV/r. Adiponectin and leptin release by adipocytes was reduced by both drugs, although to a higher extent by EFV. Neither drug affected mitochondrial DNA levels, transcripts encoding mitochondrial proteins or lactate release by adipocytes. In previously differentiated adipocytes, EFV caused a significant reduction in PPARγ and adiponectin expression, whereas LPV/r did not. We conclude that both EFV and LPV/r impair human adipogenesis, reduce adipokine release and increase the expression and release of inflammation-related cytokines, but the overall effects are greater with EFV. These findings may have implications for the pathogenesis of HIV-1-associated lipodystrophy and the development of HIV-1 therapies.

No abstract